Seminars in Pediatric Neurology
Volume 13, Issue 3 , Pages 186-197 , September 2006

Iron: A New Target for Pharmacological Intervention in Neurodegenerative Diseases

  • Megan Whitnall, BMed Sci
    • ,
  • Des R. Richardson, BSc, MSc, PhD, DSc

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Des R. Richardson, BSc, MSc, PhD, DSc, Iron Metabolism and Chelation Program, Department of Pathology, Level 5 Blackburn Building D06, University of Sydney, Sydney, New South Wales, 2006, Australia.

References 

  1. Ponka P. Hereditary causes of disturbed iron homeostasis in the central nervous system. Ann N Y Acad Sci. 2004;1012:267–281
  2. Burdo JR, Connor JR. Brain iron uptake and homeostatic mechanisms: An overview. Biometals. 2003;16:63–75
  3. Harley A, Cooper JM, Schapira AH. Iron induced oxidative stress and mitochondrial dysfunction: Relevance to Parkinson’s disease. Brain Res. 1993;627:349–353
  4. Jellinger KA. The role of iron in neurodegeneration: Prospects for pharmacotherapy of Parkinson’s disease. Drugs Aging. 1999;14:115–140
  5. Shoham S, Youdim MB. Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases. Cell Mol Biol. 2000;46:743–760
  6. Burdo JR, Connor JR. In: Iron Transport in the Central Nervous System. Molecular and Cellular Iron Transport. New York, NY: Dekker; 2002;p. 487–508
  7. Zecca L, Youdim MB, Riederer P, et al. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci. 2004;5:863–873
  8. Gaeta A, Hider RC. The crucial role of metal ions in neurodegeneration: The basis for a promising therapeutic strategy. Br J Pharmacol. 2005;146:1041–1059
  9. Gakh O, Park S, Liu G, et al. Mitochondrial iron detoxification is a primary function of frataxin that limits oxidative damage and preserves cell longevity. Hum Mol Genet. 2006;15:467–479
  10. Richardson DR, Ponka P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta. 1997;1331:1–40
  11. Ponka P, Beaumont C, Richardson DR. Function and regulation of transferrin and ferritin. Semin Hematol. 1998;35:35–54
  12. Morgan E. Transferrin biochemistry, physiology, and clinical significance. Mol Aspects Med. 1981;4:1–123
  13. Fleming MD, Trenor CC, Su MA, et al. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat Genet. 1997;16:383–386
  14. Richardson DR, Baker E. Two saturable mechanisms of iron uptake from transferrin in human melanoma cells: The effect of transferrin concentration, chelators, and metabolic probes on transferrin and iron uptake. J Cell Physiol. 1994;161:160–168
  15. Taylor EM, Morgan EH. Developmental changes in transferrin and iron uptake by the brain in the rat. Brain Res Dev Brain Res. 1990;55:35–42
  16. Roberts RL, Fine RE, Sandra A. Receptor-mediated endocytosis of transferrin at the blood-brain barrier. J Cell Sci. 1993;104:521–532
  17. Rothenberger S, Food MR, Gabathuler R, et al. Coincident expression and distribution of melanotransferrin and transferrin receptor in human brain capillary endothelium. Brain Res. 1996;712:117–121
  18. Demeule M, Poirier J, Jodoin J, et al. High transcytosis of melanotransferrin (P97) across the blood-brain barrier. J Neurochem. 2002;803:924–933
  19. Sekyere EO, Richardson DR. The membrane-bound transferrin homologue melanotransferrin: Roles other than iron transport?. FEBS Lett. 2000;483:11–16
  20. Richardson DR, Morgan EH. The transferrin homologue, melanotransferrin (p97), is rapidly catabolized by the liver of the rat and does not effectively donate iron to the brain. Biochim Biophys Acta. 2004;1690:124–133
  21. Sekyere EO, Dunn LL, Rahmanto YS, et al. Role of melanotransferrin in iron metabolism: Studies using targeted gene disruption in vivo. Blood. 2006;107:2599–2601
  22. Dunn LL, Sekyere EO, Rahmanto YS, et al. The function of melanotransferrin: A role in melanoma cell proliferation and tumorigenesis. Carcinogenesis. 2006;May 16 [Epub ahead of print]
  23. Napier I, Ponka P, Richardson DR. Iron trafficking in the mitochondrion: Novel pathways revealed by disease. Blood. 2005;105:1867–1874
  24. Richardson DR, Ponka P, Vyoral D. Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: Examination of the intermediates involved in iron metabolism. Blood. 1996;87:3477–3488
  25. Ben-Shachar D, Riederer P, Youdim MB. Iron-melanin interaction and lipid peroxidation: Implications for Parkinson’s disease. J Neurochem. 1991;57:1609–1614
  26. Double KL, Gerlach M, Schunemann V, et al. Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem Pharmacol. 2003;66:489–494
  27. Double KL, Riederer P, Gerlach M. The significance of neuromelanin in Parkinson’s disease. Drug News Dev. 1999;12:333–340
  28. Hentze MW, Kuhn LC. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc Natl Acad Sci U S A. 1996;93:8175–8182
  29. Polla BS. Therapy by taking away: the case of iron. Biochem Pharmacol. 1999;57:1345–1349
  30. Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov. 2004;3:205–214
  31. McCance R, Widdowson E. The absorption and excretion of Fe following oral and intravenous administration. J Phys. 1938;94:148–154
  32. Young AB. Huntingtin in health and disease. J Clin Invest. 2003;111:299–302
  33. Ruocco HH, Lopes-Cendes I, Laurito TL, et al. Clinical presentation of juvenile Huntington disease. Ar Qneuropsiquiatr. 2006;64:5–9
  34. Wang GH, Mitsui K, Kotliarova S, et al. Caspase activation during apoptotic cell death induced by expanded polyglutamine in N2a cells. Neuroreport. 1999;10:2435–2438
  35. Gauthier LR, Charrin BC, Borrell-Pages M, et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell. 2004;118:127–138
  36. Ross CA. Polyglutamine pathogenesis: Emergence of unifying mechanisms for Huntington’s disease and related disorders. Neuron. 2002;35:819–822
  37. Lin X, Cummings CJ, Zoghbi HY. Expanding our understanding of polyglutamine diseases through mouse models. Neuron. 1999;24:499–502
  38. Beal MF, Hyman BT, Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases?. Trends Neurosci. 1993;16:125–131
  39. Browne SE, Ferrante RJ, Beal MF. Oxidative stress in Huntington’s disease. Brain Pathol. 1999;9:147–163
  40. Goswami A, Dikshit P, Mishra A, et al. Oxidative stress promotes mutant huntingtin aggregation and mutant huntingtin-dependent cell death by mimicking proteasomal malfunction. Biochem Biophys Res Commun. 2006;342:184–190
  41. Dexter DT, Carayon A, Javoy-Agid F, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson’s disease and other neurodegenerative diseases affecting the basal ganglia. Brain. 1991;114:1953–1975
  42. Hilditch-Maguire P, Trettel F, Passani LA, et al. Huntingtin: An iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum Mol Genet. 2000;9:2789–2797
  43. Bush AI, Tanzi RE. The galvanization of beta-amyloid in Alzheimer’s disease. Proc Natl Acad Sci U S A. 2002;99:7317–7319
  44. Honda K, Casadesus G, Petersen RB, et al. Oxidative stress and redox-active iron in Alzheimer’s disease. Ann N Y Acad Sci. 2004;1012:179–182
  45. Honda K, Smith MA, Zhu X, et al. Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron. J Biol Chem. 2005;280:20978–20986
  46. Sipe JC, Lee P, Beutler E. Brain iron metabolism and neurodegenerative disorders. Dev Neurosci. 2002;24:188–196
  47. Connor JR, Snyder BS, Beard JL, et al. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer’s disease. J Neurosci Res. 1992;31:327–335
  48. Smith MA, Harris PL, Sayre LM, et al. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A. 1997;94:9866–9888
  49. Atwood CS, Huang X, Moir RD, et al. Role of free radicals and metal ions in the pathogenesis of Alzheimer’s disease. Met Ions Biol Syst. 1999;36:309–364
  50. Bishop GM, Robinson SR. B-Amyloid helps to protect neurons from oxidative stress. Neurobiol Aging. 2000;21:S226
  51. Rottkamp CA, Raina AK, Zhu X, et al. Redox-active iron mediates amyloid-beta toxicity. Free Radic Biol Med. 2001;30:447–450
  52. Rogers JT, Randall JD, Cahill CM, et al. An iron-responsive element type II in the 5′-untranslated region of the Alzheimer’s amyloid precursor protein transcript. J Biol Chem. 2002;277:45518–45528
  53. Levenson CW. Iron and Parkinson’s disease: Chelators to the rescue?. Nutr Rev. 2003;61:311–313
  54. Grunblatt E, Mandel S, Jacob-Hirsch J, et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm. 2004;111:1543–1573
  55. Mandel S, Grunblatt E, Riederer P, et al. Neuroprotective strategies in Parkinson’s disease: An update on progress. CNS Drugs. 2003;17:729–762
  56. Youdim MB, Stephenson G, Ben Shachar D. Ironing iron out in Parkinson’s disease and other neurodegenerative diseases with iron chelators: A lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci. 2004;1012:306–325
  57. Kaur D, Yantiri F, Rajagopalan S, et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: A novel therapy for Parkinson’s disease. Neuron. 2003;37:899–909
  58. Gorell JM, Ordidge RJ, Brown GG, et al. Increased iron-related MRI contrast in the substantia nigra in Parkinson’s disease. Neurology. 1995;45:1138–1143
  59. Ryvlin P, Broussolle E, Piollet H, et al. Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson’s disease. Arch Neurol. 1995;52:583–588
  60. Bartzokis G, Beckson M, Hance DB, et al. MR evaluation of age-related increase of brain iron in young adults and older normal males. Magn Reson Imaging. 1997;15:29–35
  61. Riederer P, Sofic E, Rausch WD, et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem. 1989;52:515–520
  62. Bharath S, Hsu M, Kaur D, et al. Glutathione, iron and Parkinson’s disease. Biochem Pharmacol. 2002;64:1037–1048
  63. el-Agnaf OM, Irvine GB. Aggregation and neurotoxicity of alpha-synuclein and related peptides. Biochem Soc Trans. 2002;30:559–565
  64. Faucheux BA, Martin ME, Beaumont C, et al. Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson’s disease. J Neurochem. 2002;83:320–330
  65. Thompson K, Menzies S, Muckenthaler M, et al. Mouse brains deficient in H-ferritin have normal iron concentration but a protein profile of iron deficiency and increased evidence of oxidative stress. J Neurosci Res. 2003;71:46–63
  66. Faucheux BA, Martin ME, Beaumont C, et al. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson’s disease. J Neurochem. 2003;86:1142–1148
  67. Lopiano L, Chiesa M, Digilio G, et al. Q-band EPR investigations of neuromelanin in control and Parkinson’s disease patients. Biochim Biophys Acta. 2000;1500:306–312
  68. Campuzano V, Montermini L, Molto MD, et al. Friedreich’s ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;271:1423–1427
  69. Koutnikova H, Campuzano V, Foury F, et al. Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin. Nat Genet. 1997;16:345–351
  70. De Michele G, Perrone F, Filla A, et al. Age of onset, sex, and cardiomyopathy as predictors of disability and survival in Friedreich’s disease: A retrospective study on 119 patients. Neurology. 1996;47:1260–1264
  71. Harding AE. Friedreich’s ataxia: A clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain. 1981;104:589–620
  72. Durr A, Cossee M, Agid Y, et al. Clinical and genetic abnormalities in patients with Friedreich’s ataxia. N Engl J Med. 1996;335:1169–1175
  73. Cossee M, Puccio H, Gansmuller A, et al. Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum Mol Genet. 2000;9:1219–1226
  74. Bradley JL, Blake JC, Chamberlain S, et al. Clinical, biochemical and molecular genetic correlations in Friedreich’s ataxia. Hum Mol Genet. 2000;9:275
  75. Alper G, Narayanan V. Friedreich’s ataxia. Pediatr Neurol. 2003;28:335
  76. Lodi R, Rajagopalan B, Bradley JL, et al. Mitochondrial dysfunction in Friedreich’s ataxia: From pathogenesis to treatment perspectives. Free Radic Res. 2002;36:461–466
  77. Van Driest SL, Gakh O, Ommen SR, et al. Molecular and functional characterization of a human frataxin mutation found in hypertrophic cardiomyopathy. Mol Genet Metab. 2005;85:280–285
  78. Babcock M, de Silva D, Oaks R, et al. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science. 1997;276:1709–1712
  79. Campuzano V, Montermini L, Lutz Y, et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet. 1997;6:1771–1780
  80. Foury F, Cazzalini O. Deletion of the yeast homologue of the human gene associated with Friedreich’s ataxia elicits iron accumulation in mitochondria. FEBS Lett. 1997;411:373–377
  81. Radisky DC, Babcock MC, Kaplan J. The yeast frataxin homologue mediates mitochondrial iron efflux. Evidence for a mitochondrial iron cycle. J Biol Chem. 1999;274:4497–4499
  82. Wong A, Yang J, Cavadini P, et al. The Friedreich’s ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum Mol Genet. 1999;8:425–430
  83. Rotig A, de Lonlay P, Chretien D, et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet. 1997;17:215–217
  84. Lamarche J, Shapcott D, Côté M, et al. In: Handbook of Cerebellar Diseases. New York, NY: Marcel Dekker; 1993;p. 453–458
  85. Puccio H, Simon D, Cossee M, et al. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet. 2001;27:181–186
  86. Park S, Gakh O, Mooney SM, et al. The ferroxidase activity of yeast frataxin. J Biol Chem. 2002;277:38589–38595
  87. Park S, Gakh O, O’Neill HA, et al. Yeast frataxin sequentially chaperones and stores iron by coupling protein assembly with iron oxidation. J Biol Chem. 2003;278:31340–31351
  88. O’Neill HA, Gakh O, Park S, et al. Assembly of human frataxin is a mechanism for detoxifying redox-active iron. Biochemistry. 2005;44:537–545
  89. Eaton JW, Qian M. Molecular bases of cellular iron toxicity. Free Radic Biol Med. 2002;32:833–840
  90. Seznec H, Simon D, Monassier L, et al. Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia. Hum Mol Genet. 2004;13:1017–1024
  91. Seznec H, Simon D, Bouton C, et al. Friedreich ataxia: The oxidative stress paradox. Hum Mol Genet. 2005;14:463
  92. Schulz JB, Dehmer T, Schols L, et al. Oxidative stress in patients with Friedreich ataxia. Neurology. 2000;55:1719–1721
  93. Bradley JL, Homayoun S, Hart PE, et al. Role of oxidative damage in Friedreich’s ataxia. Neurochem Res. 2004;29:561–567
  94. Chaston TB, Richardson DR. Iron chelators for the treatment of iron overload disease: Relationship between structure, redox activity, and toxicity. Am J Hematol. 2003;73:200–210
  95. Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev. 2005;57:547–583
  96. Richardson DR, Mouralian C, Ponka P, et al. Development of potential iron chelators for the treatment of Friedreich’s ataxia: Ligands that mobilize mitochondrial iron. Biochim Biophys Acta. 2001;1536:133–140
  97. Liu ZD, Hider RC. Design of clinically useful iron(III)-selective chelators. Med Res Rev. 2002;22:26–64
  98. Harris DC, Aisen P. Facilitation of Fe(II) autoxidation by Fe(3) complexing agents. Biochim Biophys Acta. 1973;329:156–158
  99. Tillbrook GS, Hider RC. Iron chelators for clinical use. In:  Sigel A,  Sigel H editor. Metal Irons in Biological Systems. vol 35:New York, NY: Marcel Dekker; 1998;p. 691–730
  100. Hollander D, Ricketts D, Boyd CAR. Importance of probe molecular geometry in determining intestinal permeability. Can J Gastroenterol. 1988;2:35A–38A
  101. Oldendorf WH. Lipid solubility and drug penetration of the blood brain barrier. Proc Soc Exp Biol Med. 1974;147:813–815
  102. Maxton DG, Bjarnason I, Reynolds AP, et al. Lactulose, 51Cr-labelled ethylenediaminetetra-acetate. L-rhamnose and polyethyleneglycol 400 [corrected] as probe markers for assessment in vivo of human intestinal permeability Clin Sci (Lond). 1986;71:71–80
  103. Richardson DR, Wis Vitolo LM, Hefter GT, et al. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Part I. Ionization characteristics of the ligands and their relevance to biological properties. Inorg Chim Acta. 1990;170:165–170
  104. Florence A, Attwood D. Physicochemical principles of pharmacy. London: Macmillan; 1988;
  105. Cunningham MJ, Nathan DG. New developments in iron chelators. Curr Opin Hematol. 2005;12:129–134
  106. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89:739–761
  107. Aouad F, Florence A, Zhang Y, et al. Evaluation of new iron chelators and their therapeutic potential. Inorg Chim Acta. 2002;339:470–480
  108. Wong CS, Kwok JC, Richardson DR. PCTH: A novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice. Biochim Biophys Acta. 2004;1739:70–80
  109. Ben-Shachar D, Eshel G, Finberg JP, et al. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem. 1991;56:1441–1444
  110. Lan J, Jiang DH. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J Neural Transm. 1997;104:469
  111. Pierre JL, Baret P, Serratrice G. Hydroxyquinolines as iron chelators. Curr Med Chem. 2003;10:1077–1084
  112. Martell A, Smith R. Critical Stability Constants. New York: Plenum Press; 1977;
  113. Jonas SK, Riley PA. The effect of ligands on the uptake of iron by cells in culture. Cell Biochem Funct. 1991;9:245–253
  114. Frederickson CJ, Kasarskis EJ, Ringo D, et al. A quinoline fluorescence method for visualizing and assaying the histochemically reactive zinc (bouton zinc) in the brain. J Neurosci Methods. 1987;20:91–103
  115. Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron. 2001;30:665–676
  116. Zheng H, Youdim MB, Weiner LM, et al. Synthesis and evaluation of peptidic metal chelators for neuroprotection in neurodegenerative diseases. J Pept Res. 2005;66:190–203
  117. Bush AI. Metal complexing agents as therapies for Alzheimer’s disease. Neurobiol Aging. 2002;23:1031–1038
  118. Shiraki H. The neuropathology of subacute myelo-optico-neuropathy, “SMON”, in the humans: With special reference to the quinoform intoxication. Jpn J Med Sci Biol. 1975;28(Suppl):101–164
  119. Yassin MS, Ekblom J, Xilinas M, et al. Changes in uptake of vitamin B(12) and trace metals in brains of mice treated with clioquinol. J Neurol Sci. 2000;173:40–44
  120. Jenagaratnam L, McShane R. Clioquinol for the treatment of Alzheimer’s Disease. Cochrane Database Syst Rev. 1. 2006;CD005380
  121. Nguyen T, Hamby A, Massa SM. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington’s disease mouse model. Proc Natl Acad Sci U S A. 2005;102:11840–11845
  122. Ritchie CW, Bush AI, Mackinnon A, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: A pilot phase 2 clinical trial. Arch Neurol. 2003;60:1685–1691
  123. Atwood CS, Scarpa RC, Huang X, et al. Characterization of copper interactions with alzheimer amyloid beta peptides: Identification of an attomolar-affinity copper binding site on amyloid beta1-42. J Neurochem. 2000;75:1219–1233
  124. Ponka P, Borova J, Neuwirt J, et al. Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett. 1979;97:317–321
  125. Hoy T, Humphrys J, Jacobs A, et al. Effective iron chelation following oral administration of an isoniazid-pyridoxal hydrazone. Br J Haematol. 1979;43:443–449
  126. Brittenham GM. Pyridoxal isonicotinoyl hydrazone: An effective iron-chelator after oral administration. Semin Hematol. 1990;27:112–116
  127. Richardson DR, Hefter GT, May PM, et al. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. III. Formation constants with calcium(II), magnesium(II) and zinc(II). Biol Met. 1989;2:161–167
  128. Richardson DR, Vitolo L, Hefter GT, et al. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Part I. Ionisation characteristics of the ligand and their relevance to biological properties. Inorg Chim Acta. 1990;170:165–170
  129. Ponka P, Richardson DR, Edward JT, et al. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Relationship of the lipophilicity of the apochelator to its ability to mobilise iron from reticulocytes in vitro. Can J Physiol Pharmacol. 1994;72:659–666
  130. Johnson DK, Pippard MJ, Murphy TB, et al. An in vivo evaluation of iron-chelating drugs derived from pyridoxal and its analogs. J Pharmacol Exp Ther. 1982;221:399–403
  131. Richardson DR, Tran EH, Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood. 1995;86:4295–4306
  132. Becker E, Richardson DR. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs. J Lab Clin Med. 1999;134:510–521
  133. Richardson DR, Ponka P. Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease. J Lab Clin Med. 1998;131:306–315
  134. Richardson DR, Becker E, Bernhardt PV. The biologically active iron chelators 2- pyridylcarboxaldehyde isonicotinoyl hydrazone, 2-pyridylcarboxaldehyde benzoyl hydrazone and 2-furfural isonicotinoyl hydrazone. Acta Crystallographica Section C. 1999;C55:2102–2105
  135. Bernhardt PV, Chin P, Richardson DR. Unprecedented oxidation of a biologically active aroylhydrazone chelator catalysed by iron(III): Serendipitous identification of diacylhydrazine ligands with high iron chelation efficacy. J Biol Inorg Chem. 2001;6:801–809
  136. Richardson DR. Friedreich’s ataxia: Iron chelators that target the mitochondrion as a therapeutic strategy?. Expert Opin Investig Drugs. 2003;12:235–245
  137. Klausner RD, Dancis A. A genetic approach to elucidating eukaryotic iron metabolism. FEBS Lett. 1994;355:109–113
  138. Hassett R, Dix DR, Eide DJ, et al. The Fe(II) permease Fet4p functions as a low affinity copper transporter and supports normal copper trafficking in Saccharomyces cerevisiae. Biochem J. 2000;351:477–484

 Supported by the Muscular Dystrophy Association, Friedreich’s Ataxia Research Alliance, Friedreich’s Ataxia Research Alliance, and National Health and Medical Research Council, for grant and fellowship support. M.W was supported by a University of Sydney Australian Postgraduate Award.

PII: S1071-9091(06)00107-0

doi: 10.1016/j.spen.2006.08.008

Seminars in Pediatric Neurology
Volume 13, Issue 3 , Pages 186-197 , September 2006

Article Tools

* Image Usage & Resolution